湿性年龄相关性黄斑变性药物治疗进展  

Advances in drug therapy for wet age-related macular degeneration

作　　者：石卫峰[1] 归成[1] 李晓宇[1] 刘皋林[1] 

机构地区：[1]上海交通大学附属第一人民医院临床药学科,上海200080

出　　处：《中国新药杂志》2014年第18期2161-2164,共4页Chinese Journal of New Drugs

摘　　要：年龄相关性黄斑变性(AMD)是导致失明主要原因,AMD分为干性和湿性两种,湿性AMD更可能对视力产生严重危害。湿性AMD的治疗在过去的10年发生了巨大变化。血管内皮生长因子(VEGF)抑制剂玻璃体内注射的治疗方法已成为湿性AMD的标准治疗,光敏剂的光动力疗法及激光治疗逐渐被取代。临床使用的VEGF抑制剂中雷珠单抗、阿柏西普和贝伐珠单抗的疗效相似,贝伐珠单抗的治疗费用较低,康柏西普是我国自主研发的药物,已被批准上市。该类药物的长期疗效和安全性需要进一步观察。Age-related macular degeneration （AMD） is the leading cause of visual loss in the elderly. AMD includes dry AMD and wet AMD. Wet AMD is more likely to lead to significant visual loss. The treatment of wet AMD changed over the past 10 years. Intravitreal injections of vascular endothelial growth factor （VEGF） inhibitor has become the gold standard for treating wet AMD, which gradually replaced photodynamic therapy with photosensitizers and laser therapy. Evidence suggests that bevacizumab, ranibizumab and aflibercep have similar efficacy, and bevacizumab costs less. Conbercept, developed independently by China, has been approved for marketing. The long-term efficacy and safety of VEGF inhibitors need further study.

关 键 词：年龄相关性黄斑变性 血管内皮生长因子抑制剂 维替泊芬 雷珠单抗 贝伐珠单抗 阿柏西普 康柏西普 

分 类 号：R988.1[医药卫生—药品]